Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran

por Seyedifar, Meysam, Sabouri, Menhajuddin, Soodi, Omid, Ghasemi, Hananeh
Publicado 2023

Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride

por Khedmati, Jamaleddin, Soleymani, Fatemeh, Moosivand, Asiye, Zartab, Saman, Seyedifar, Meysam
Publicado 2021

Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran

por Saiyarsarai, Parisa, Khorasani, Elahe, Photogeraphy, Hasti, Ghaffari Darab, Mohsen, Seyedifar, Meysam
Publicado 2020

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis

por Saiyarsarai, Parisa, Robabpour Derakhshan, Atefeh, Khedmati, Jamaleddin, Eshghi, Peyman, Seyedifar, Meysam
Publicado 2021

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective

por Zargaran, Marzieh, Soleymani, Fatemeh, Nasrollahi, Saman Ahmad, Seyedifar, Meysam, Rahaghi, Mohammad Mehdi Ashrafian
Publicado 2021

Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran

por Seyedifar, Meysam, Dorkoosh, Farid Abedin, Hamidieh, Amir Ali, Naderi, Majid, Karami, Hossein, Karimi, Mehran, Fadaiyrayeny, Masoomeh, Musavi, Masoumeh, Safaei, Sanaz, Ahmadian-Attari, Mohammad Mahdi, Hadjibabaie, Molouk, Cheraghali, Abdol Majid, Akbari Sari, Ali
Publicado 2016